Klaas, Julian E. http://orcid.org/0000-0003-3207-4517
Rechl, Philip http://orcid.org/0000-0001-8982-7749
Feucht, Nikolaus http://orcid.org/0000-0001-9848-0070
Siedlecki, Jakob http://orcid.org/0000-0002-0279-4823
Friedrich, Julia
Lohmann, Chris P.
Maier, Mathias http://orcid.org/0000-0003-4165-4003
Funding for this research was provided by:
Klinikum rechts der Isar der Technischen Universität München
Article History
Received: 17 November 2020
Revised: 12 January 2021
Accepted: 5 February 2021
First Online: 6 March 2021
Declarations
:
: Approval for this retrospective cohort study was obtained from the ethics committee of Technical University of Munich. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
: J Klaas reports personal fees from Novartis, outside of the submitted work. N Feucht reports personal fees from Novartis, Allergan, Bayer, and Heidelberg Engineering, outside the submitted work. J Siedlecki received previous speaker fees and travel expenses from Novartis Pharma GmbH, Carl Zeiss Meditec AG, Oculentis OSD Medical GmbH, and Pharm-Allergan GmbH. Jakob Siedlecki received personal consultation fees from Novartis Pharma GmbH, Bayer AG, and Pharm-Allergan GmbH. Jakob Siedlecki received travel support from Oertli AG. M Maier reports speaker honoraria from Novartis, Allergan, Bayer, Heidelberg Engineering, and Zeiss, Clinical Trials (Bayer, Novartis, Roche), outside the submitted work. P Rechl, J Friedrich, and CP Lohmann have nothing to disclose.